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Abstract 
 
Cyanobacterial lipopolysaccharide/s (LPS) are frequently cited in the cyanobacteria 
literature as toxins responsible for a variety of heath effects in humans, from skin 
rashes to gastrointestinal, respiratory and allergic reactions. The attribution of toxic 
properties to cyanobacterial LPS dates from the 1970s, when it was thought that lipid 
A, the toxic moiety of LPS, was structurally and functionally conserved across all 
Gram-negative bacteria. However, more recent research has shown that this is not the 
case, and lipid A structures are now known to be very different, expressing properties 
ranging from LPS agonists, through weak endotoxicity to LPS antagonists. Although 
cyanobacterial LPS is widely cited as a putative toxin, most of the small number of 
formal research reports describe cyanobacterial LPS as weakly toxic compared to LPS 
from Enterobacteriaceae.  
 
In order to place the biological activity of cyanobacterial LPS in the context of the 
much more widely studied LPS of Gram-negative bacteria, particularly Escherichia 
coli and Salmonella spp, relevant aspects of the broader immunology, microbiology 
and structural biochemistry literature will be reviewed. 
 
There is a danger that what was initially speculation about cyanobacterial LPS may 
evolve into orthodoxy without basis in research findings. No cyanobacterial lipid A 
structures have been described and published to date, so a recommendation is made 
that cyanobacteriologists should not continue to attribute such a diverse range of 
clinical symptoms to cyanobacterial LPS without research confirmation. Indeed, many 
of the symptoms ascribed to cyanobacterial LPS only seem to appear in the 
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cyanobacteria literature, and were not found in the literature describing toxic effects 
of the much more widely studied heterotrophic bacterial LPS. 
 
 
 
Introduction 
 
Cyanobacterial LPS is attributed with a range of pathological effects in humans, from 
gastro-intestinal illness, cutaneous signs and symptoms, allergy, respiratory disease, 
headache and fever. This review will present the studies of cyanobacterial LPS, and 
will attempt to place the knowledge of these products within the broader 
understanding of LPS from Gram-negative heterotrophic bacteria. The paper will 
present an overview of the mechanisms of toxicity of Gram-negative bacterial LPS, 
discussing the history of its discovery and the present perception of its pathogenicity.  
 
 
Cyanobacterial LPS and symptoms in humans 
 
Table 1 lists some of the signs and symptoms reportedly associated with exposure to 
cyanobacterial LPS, and references that imply particular symptoms or symptom 
groups are explained by such exposures. Table 1 does not present an exhaustive list of 
citations implicating cyanobacterial LPS with human illness. Many such references 
are found in review articles, and the table does not include citations which discuss 
cyanobacterial LPS in the context of cyanobacterial toxins without linking them to 
specific illnesses – e.g. “Cyanobacterial toxins are of three main types: 
lipopolysaccharide endotoxins, hepatotoxins, and neurotoxins.” [1]; “Potential irritant; 
affects any exposed tissue” [2, 3]; “(LPS) are responsible for the irritant nature of 
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cyanobacterial material” [4]; and “…toxicants such as…lipopolysaccharide 
endotoxins…affect any exposed tissue…” [5].  
  
 Several authors note that the health implications of cyanobacterial LPS are poorly 
understood and the topic requires more research [6-15]. Only one reference was found 
in the cyanobacteria literature that raises doubts about illness caused by cyanobacterial 
LPS: Carmichael [16] suggests that the relationship between ingested LPS and illness 
in an immunologically competent population is debatable, there being little evidence 
that people with a normal LPS-containing gut flora would be affected by LPS from 
water supplies.  
 
The relationship between cyanobacterial LPS and illness is discussed in language 
ranging from cautious: “…may be responsible…” [17], “possibly (due to) 
lipopolysaccharides” [15], to definitive: “dermatotoxins” [18] and “dermatotoxic 
lipopolysaccharides” [19, 20]. Cyanobacterial LPS has also been implicated as the 
cause of an outbreak of pyrogenic reactions in a haemodialysis clinic in 1974 [21].  
 
The references in the literature to the association between cyanobacterial LPS and this 
rather diverse range of symptoms are not based on any research evidence specific to 
cyanobacterial LPS. As will be discussed later in this review, the few toxicological 
investigations that have been carried out to date are mostly limited to the end-points of 
lethality and the local Shwartzman reaction, in which sequential subcutaneous and 
intravenous injections of LPS produce a dermonecrotic lesion in rabbit skin. Rather, 
symptomatology attributed to contact with cyanobacterial LPS appears to be 
something of a default diagnosis for illnesses that are not otherwise explained by the 
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current knowledge of cyanobacterial exotoxins, most of which are somewhat specific 
to their target organ system.  
 
The most likely explanation for the ready attribution of these illnesses to 
cyanobacterial LPS lies in the realisation that LPS from Gram-negative heterotrophic 
bacteria are implicated in significant morbidity – and mortality – so cyanobacteria, 
which are widely but somewhat inaccurately accepted as Gram-negative bacteria may 
equally be responsible for illness because they contain LPS.  Codd  makes such a 
proposition, suggesting that: “The LPS of other bacteria are associated with 
gastroenteritis and inflammation problems and it is thought that cyanobacterial LPS 
may contribute to waterborne health incidents although this possibility has not been 
adequately investigated” [13].  
 
There is a risk that speculative attribution of symptoms in humans to environmental 
exposure to cyanobacterial LPS will continue without an appropriate and specific 
research foundation. This review will attempt to examine more closely the 
mechanisms by which LPS from Gram-negative heterotrophic bacteria is associated 
with morbidity, and compare and contrast cyanobacterial LPS and heterotrophic 
bacterial LPS.  
 
 
Cyanobacteria: Gram-negative or Gram-positive? 
 
Most references to cyanobacteria describe these organisms as Gram-negative 
prokaryotes [17, 22-24, 25 (p.97), 26]. Weckesser et al [27] state that the presence of 
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LPS is evidence for the Gram-negative cell wall architecture of cyanobacteria. 
However, Weckesser et al [28] reported that a strain of Anabaena variabilis they 
investigated was Gram-positive, “like other blue-green algae…”. Drews [29] also 
classifies cyanobacteria as Gram-positive. Golecki [30] reviewed electron microscopy 
studies of the cell wall architecture of various bacteria, and suggested that 
cyanobacteria have characteristics of both Gram-negative and Gram-positive 
organisms. They contain an outer membrane and LPS, which are defining 
characteristics of Gram-negative bacteria [31, 32], and a thick, highly cross-linked 
peptidoglycan layer similar to Gram-positive organisms. Jürgens & Weckesser [33] 
and Golecki [30] suggest that the chemical and structural organisation of the cell wall 
may place cyanobacteria in a separate phylogenetic category to both Gram-negative 
and Gram-positive bacteria, with cyanobacteria developing independently of Gram-
negative and Gram-positive bacteria from a common ancestor. However, according to 
Margulis & Schwartz [34 (p.78)], electron microscopy shows that cyanobacteria have 
Gram-negative cell walls.  
 
 
Terminology: “endotoxin” in the cyanobacteria literature 
 
While most references to endotoxin in the cyanobacteria literature (e.g. those in Table 
1) are clearly referring to LPS, i.e. cell wall structural components, this is not always 
the case. Several authors discuss “endotoxins” when they were obviously describing 
the toxic properties of microcystins [35-40]. Kay [41] refers to aphantoxin (now 
known as saxitoxins) from Aphanizomenon flos-aquae as an “alkaloid endotoxin”. 
Gentile & Maloney [42] also labelled what were presumably saxitoxins as an 
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endotoxin. Even as recently as 2000, cyanobacterial hepatotoxins and neurotoxins 
were being described as endotoxins [43]. This misunderstanding of the nomenclature 
is also seen in biotoxin research fields outside of cyanobacteria, with brevetoxins 
described as endotoxins [44]. Immunologists clearly understand endotoxins to refer 
only to LPS of Gram-negative bacteria. The reader’s attention is drawn to this 
distinction, as throughout this review “endotoxin” and “LPS” are used more or less 
interchangeably, whereas other cyanobacterial toxins such as microcystins, 
cylindrospermopsin, saxitoxins and anatoxin-a, when discussed in aggregate are 
referred to as “exotoxins”. The history of the term “endotoxin” and its current use are 
discussed in the following section.  
 
 
Gram-negative bacterial LPS: Introduction and its discovery 
 
LPS from many bacterial species will initiate acute inflammatory responses in 
mammals that are typical of the host reaction to tissue injury or infection [45]. LPS 
can induce a large and diverse range of effects, ranging from pyrexia to Gram-
negative septic shock, which manifests as a complex and dramatic syndrome 
involving fever, leucopoenia, hypotension, cardiopulmonary dysfunction, 
disseminated intravascular coagulation and multi-system failure [46, 47 (p.172)].  
 
The history of the understanding of LPS starts in the late nineteenth century, when 
Richard Pfeiffer used heat-inactivated lysates of Vibrio cholerae to provoke 
pathophysiological effects in guinea pigs [46]. Pfeiffer named the heat-stable and cell-
associated toxic substance “endotoxin”, to distinguish it from the heat-labile and 
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proteinaceous exotoxins, which were known to be secreted by replicating bacteria [46, 
47 (p.139), 48, 49]. Initial analyses of endotoxin revealed that it contained 
polysaccharide and lipid, and was thus named lipopolysaccharide. The terms 
“endotoxin” and “lipopolysaccharide” are widely used by workers in a variety of 
biomedical fields as synonyms to describe the same molecule (many references, e.g. 
[46, 49-55] including the field of cyanobacteria  research: “lipopolysaccharide 
endotoxins” [20, 56-58]. However, some authors have suggested that LPS should refer 
to the purified molecule, whereas endotoxin more appropriately describes 
macromolecular complexes of LPS, protein, phospholipid and nucleic acids [47 
(p.137), 48, 59].  
 
The study of LPS, which was largely concerned with investigating fever, progressed 
in the late 1940s with the discovery of endogenous pyrogens [47 (pp.168-71)]. Since 
then, the field of cytokine biology has made enormous strides. It is now understood 
that the pathological effects of LPS are indirect, i.e. LPS acts by initiating a cascade of 
host-mediated responses: initially monocytes and macrophages are stimulated, and 
then neutrophils and platelets congregate in microcapillaries, causing vascular injury. 
Inflammatory cells release a range of endogenous mediators, including arachidonic 
acid metabolites, platelet-activating factor, cytokines such as interleukin-1 (IL-1), IL-6 
and tumour necrosis factor-alpha (TNF-α), nitric oxide, toxic O2 metabolites, 
vasoactive amines, proteases and products of the complement and coagulation 
cascades. There are many reviews in the literature on cytokines and LPS - some recent 
examples are: [45-47, 49, 53, 54, 60, 61]. Cytokine-mediated responses are extremely 
complex: cytokines are pleiotropic, i.e. a single type of cytokine affects several 
different types of cell. Cytokines have autocrine effects, i.e. they can stimulate the 
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cells that secrete them to produce more cytokines, and paracrine effects – stimulating 
other cells to produce different cytokines [62]. Signs and symptoms in human 
volunteers after administration of endotoxin are: fever, rigors, and influenza-like 
symptoms of fatigue, headache, nausea, myalgia, arthralgia, drowsiness, mild amnesia 
and diarrhoea [45, 59, 63, 64]. 
 
From the discovery that LPS-associated pathology results from the stimulation of host 
cell responses came the realisation that LPS binds to specific receptors in order to 
elicit the release of cytokines and other inflammatory mediators [61]. Several 
membrane-bound and soluble proteins have been shown to bind LPS; the most 
important appear to be CD14 and LPS-binding protein (LBP) [46, 49, 50, 53, 61, 65]. 
The Toll-like receptor (TLR) family are a recently discovered group of 
transmembrane receptors that are fundamental in signalling innate immune responses 
to conserved microbial structures, and they are also involved in the recognition of 
some endogenous ligands. TLR4 is instrumental in signalling LPS from many Gram-
negative bacteria, and TLR2 is involved in the recognition of some unusual LPS. 
There is a considerable and rapidly expanding body of literature on the TLR family; 
one of the most comprehensive reviews is by Takeda et al [66]. A review by Janeway 
and Medzhitov [67] is an excellent introduction to TLRs, and places the activity of 
these receptors in the broader context of innate immunity.  
 
Knowledge of the role of specific receptors in mammalian hosts has led to the 
demonstration that LPS itself is non-toxic. Schnaitman notes that “LPS itself is not 
toxic” [68] and Henderson et al describe LPS as “relatively inactive” and observe that 
several host proteins are necessary for LPS to display full agonist potency [47 
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(p.173)]. CD14-deficient cell lines such as Chinese hamster ovary are unresponsive to 
LPS at high doses, and cell lines that show poor LPS activation can be converted to 
show high activation when transfected with the CD14 gene [68]. LPS-unresponsive 
mouse strains and cytokine knockout strains also serve to reinforce the concept that 
LPS is not directly toxic, and the pathophysiology associated with Gram-negative LPS 
results from host-mediated factors [65, 69-74].  
 
 
LPS structure – similarities and differences across Gram-negative 
bacteria 
 
LPS from different Gram-negative species apparently share common features in their 
basic architecture. A structure consisting of four covalently linked segments – a 
surface carbohydrate polymer (O-specific chain), a core oligosaccharide featuring an 
outer and inner region, and an acylated glycolipid (termed lipid A) is seen in such 
ecologically diverse bacteria as Salmonella, Pseudomonas, Vibrio and Rhizobium 
[75]. The O-specific chain shows the most diversity, and is the basis for serological 
specificity [46], while lipid A, which anchors the LPS molecule in the Gram-negative 
outer membrane, is the most conserved biochemical structure across different bacterial 
species [69] (See Figure 1). There is unequivocal acceptance that the lipid A moiety is 
the biologically active component of LPS [76]. This was confirmed by the 
observations that LPS from polysaccharide-deficient mutant strains were equally as 
bioactive as parent LPS [69, 77], and chemically synthesised Escherichia coli lipid A 
exhibits identical activity to natural E. coli lipid A [78].  
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Are all LPS equal in terms of their host-mediated responses? 
 
Although the basic structure of lipid A is seen in phylogenetically diverse Gram-
negative bacteria, variations in the nature and location of acyl groups or alterations in 
the hydrophilic backbone can result in partial or total loss of biological activity [46, 
49, 79, 80]. An example is seen in the case of some purple non-sulfur bacteria, which 
could be considered to be somewhat more representative of cyanobacteria when it 
comes to drawing comparisons on the biological activity of LPS. Purple non-sulfur 
bacteria, being photosynthetic, are Gram-negative bacteria that occupy a similar 
ecological niche to that of cyanobacteria, and therefore have growth and reproductive 
strategies that much more closely resemble cyanobacteria than the heterotrophic, gut-
dwelling E. coli and Salmonella. Lipid A from Rhodobacter sphaeroides and 
Rhodobacter capsulatus is not only inactive, but is an antagonist of 
Enterobacteriaceae LPS-induced cell activation [46, 47 (pp.157, 297-8), 50, 81]. R. 
sphaeroides and R. capsulatus lipid A differs from that of Escherichia coli in several 
respects, all relating to the acylation pattern; the lack of endotoxic activity in R. 
sphaeroides and R. capsulatus appears to be attributable to the presence of five rather 
than six fatty acid groups, and the shorter chain lengths (C10 in R. sphaeroides and R. 
capsulatus compared with C14 in E. coli) in two ester-linked fatty acids [81]. Lipid A 
from R. sphaeroides and R. capsulatus is of pharmacological interest because of their 
LPS-antagonist properties; these lipid A structures and some synthetic derivatives 
have been shown to be potent LPS antagonists in vitro and to protect against LPS-
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induced morbidity and mortality in animal models [47 (p.298), 75, 82]. Competitive 
inhibition of biologically active LPS by LPS antagonists further illuminates the 
requirement for host cell receptor sites in mediating the responses to LPS [50].  Other 
purple non-sulfur bacteria, e.g. Rhodopseudomonas viridis and Rhodopseudomonas 
palustris are also reported to lack endotoxic activity [27, 81], but the lipid A from 
another purple non-sulfur bacterium, Rubrivivax gelatinosus, is reportedly associated 
with high lethality in mice – at similar doses that cause lethality in Salmonella – and 
high pyrogenicity in rabbits [27, 81]. The high endotoxicity of R. gelatinosus is 
apparently due to the presence of six fatty acid groups in the lipid A structure [81, 83].  
 
Bacteroides spp, which are common gut and periodontal commensals, have low 
endotoxic activity compared to that of Salmonella, with a greater than 500-fold higher 
mouse LD50 and 100 to 1,000-fold reduced ability to stimulate production of IL-1 in 
monocyte cultures [84, 85]. Bacteroides fragilis LPS inhibits E. coli LPS-induced 
endothelial adhesiveness for polymorphonuclear leucocytes, although B. fragilis LPS 
is reported to be directly toxic to endothelial cell cultures at high concentrations [50]. 
In a study of cytokine induction in whole blood, Frieling et al [86] showed that B. 
fragilis stimulated IL-1β, IL-6 and IL-1ra at levels comparable to Gram-positive 
bacteria, where 100 to 1,000-fold more organisms are required to produce similar 
concentrations of cytokines than with common pathogenic Gram-negative bacteria. 
Wilson et al [87] suggest that B. fragilis may be such a weak cytokine inducer 
because, being a dominant organism in normal gut flora, it has evolved mechanisms to 
downregulate the synthesis of inflammatory cytokines in order to optimise their niche 
in the host gut. B. fragilis has five fatty acyl groups in the lipid A moiety, and other 
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structural differences to Salmonella and E. coli LPS, such as a monophosphorylated 
disaccharide backbone and longer fatty acyl chains [88].  
 
Some pathogenic bacteria have LPS which reflects the highly specific niches they 
inhabit: enteric Gram-negative bacteria have long, hydrophilic and neutral O-specific 
polysaccharide chains which protects the organism from solubilisation by bile acids 
and intestinal enzymes, whereas organisms that colonise the mucous membranes of 
the respiratory and genital tracts have outer membrane surfaces that are hydrophobic 
and can be solubilized by bile [89, 90]. Gram-negative bacteria such as Neisseria, 
Haemophilus and Bordetella have developed unique surface glycolipids lacking O-
antigens, which some workers call lipooligosaccharides [89, 90].  
 
The presence of one or more secondary acyl chains appears to be essential for lipid A 
to stimulate some endotoxic reactions [79, 85]. One of the final stages of 
Enterobacteriaceae lipid A biosynthesis is the formation of acyloxyacyl groups, so-
called secondary fatty acids [91]. A leucocyte enzyme, acyloxyacyl hydrolase, 
selectively removes these secondary fatty acyl groups, without releasing the 3-
hydroxy acyl chains that substitute the lipid A disaccharide backbone [79, 92]. 
Deacylated LPS from E. coli, Salmonella typhimurium, Haemophilus influenzae and 
Neisseria meningitidis were shown to have reduced activities in a series of tests 
relating to endotoxic potential, in some cases by greater than two orders of magnitude, 
and deacylated Neisseria LPS demonstrated some antagonistic activity towards 
Neisseria and Salmonella LPS [79, 92, 93]. 
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The lipid A analog, compound 406, which lacks the two secondary fatty acids of E. 
coli lipid A, is unable to induce cytokines in human cells [46, 49, 72]. Rietschel et al 
[49] propose that endotoxic capacity resides in the spatial conformation of lipid A, in 
that biologically inactive lipid A (e.g. R. capsulatus) conforms to lamellar structures, 
whereas endotoxic lipid A adopts exclusively cubic or hexagonal structures.  
 
Netea et al [94] suggest that the historical assumption that LPS from different Gram-
negative bacteria possess similar biological effects is incorrect, and that differences 
between LPS across species are the rule rather than the exception. The authors discuss 
structure-function relationships between LPS and the Toll-like receptors (TLRs), 
which are integral in LPS-mediated signalling, suggesting that differences in the three-
dimensional conformation of LPS molecules translate into differences in TLR 
signalling of proinflammatory cytokines. In their reviews of the supramolecular 
structure and phase transition states of LPS and lipid A, Seydel and Brandenburg [95] 
and Seydel et al [52] suggest that endotoxic activity is related to the three-dimensional 
conformation of LPS and the multimeric aggregates they form. The conformation of 
LPS or lipid A within such aggregates is not constant, but a reversible phase transition 
occurs, which is temperature-dependent and related to the length and degree of 
saturation of the acyl chains and other physiological conditions.  
 
More recent work by Seydel and collaborators has led to the realisation that the 
biological activity of specific lipid A structures can be determined by an 
understanding of the its supramolecular structure, which is a function of the 
monomeric conformation, which in turn is largely determined by the primary 
molecular structure [80, 96, 97]. The presence of sufficient negative charges on the 
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disaccharide backbone – mainly, but not necessarily, two phosphate groups – has an 
important influence on lipid A molecular conformation and the binding capacity to 
serum proteins such as LBP [80, 98]. A high negative charge density is reported to be 
an essential requirement for agonistic and antagonistic properties; complete or partial 
substitution of negative charges can result in the loss of all biological activity [80, 99]. 
Seydel’s team now suggest that a general principle can be applied regarding the 
molecular conformation of lipid A structures and their biological activity: lipid A 
structures that adopt conical/concave shapes have hexagonal or cubic supramolecular 
aggregate structures and express high endotoxic potential, whereas lipid A structures 
that adopt cylindrical conformations have lamellar aggregates and are either inactive 
or LPS antagonists [96]. Thus lipid A of the photosynthetic bacterium R. gelatinosus, 
which has high endotoxic activity [27, 81], was seen to adopt hexagonal aggregate 
structures, whereas the lipid A of other non-endotoxic photosynthetic bacteria adopt 
cylindrical shapes and lamellar aggregate structures [96, 97, 100]. Lipid A from 
Chromobacterium violaceum forms a cylindrical geometry and is reportedly three 
orders of magnitude less active than E. coli lipid A [101]. Ulmer et al [102] also found 
that a synthetic lipid A structure based on C. violaceum lipid A had markedly lower 
cytokine-inducing capacity than an E. coli-based synthetic lipid A. These findings are 
in contrast to some other reports, which describe C. violaceum lipid A as having a 
high agonist activity [49, 72]. Of interest is the observation that the primary lipid A 
structures of C. violaceum and R. gelatinosus are very similar (bisphosphorylated 
diglucosamine backbone, six symmetrically distributed acyl chains differing only in 
the length of the two acyloxyacyl groups: C=12 in C. violaceum and C=10 for R. 
gelatinosus) [81]. Yet C. violaceum lipid A is an LPS antagonist, whereas R. 
gelatinosus lipid A expresses high agonist activity. Seydel et al [101] suggest that the 
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chemical structures of these two lipid A’s may need to be re-examined. Lipid A of 
Campylobacter jejuni, which has low endotoxic potential, shows a very slight 
tendency to adopt a conical/concave shape, whereas the lipid A of E. coli clearly 
adopts a conical/concave form [96, 103].  
 
As a result of these studies, the ability of a lipid A monomer to adopt a conical shape 
(the so-called endotoxic conformation) has been described as a prerequisite for 
endotoxicity [97]. Seydel et al [101] suggest that when lipid A molecules are 
intercalated into target cell membranes, only lipid A which forms a conical shape – 
where the cross-sectional area of the hydrophilic backbone is smaller than the cross 
section of the hydrophobic acyl groups – can exert a mechanical stress on signalling 
proteins. LPS with a lipid A moiety which assumes a cylindrical shape – cross-
sectional areas of the hydrophobic and hydrophilic components being roughly equal – 
will occupy the binding site but be unable to activate signalling proteins, thus acting 
as an LPS antagonist [99, 101]. The number and distribution of acyl chains has been 
shown to affect the tilt angle of the disaccharide backbone with respect to the target 
cell membrane; the orientation of the backbone sugars appears to correlate with the 
endotoxic potential of the LPS. The lipid A molecular shape and the tilt angle of the 
backbone sugars are reported to be the complete determinants of endotoxic activity 
[99, 101].  
 
The discussion above has contrasted the endotoxic potential of lipid A structures from 
the most widely studied forms, those of the Enterobacteriaceae, with some unusual 
lipid A’s from photosynthetic bacteria and synthetic lipid A analogs. The reason that 
cyanobacterial LPS has not been discussed here is simply that the required research 
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has not been done as yet. No cyanobacterial lipid A structures have been published, 
therefore no inferences can be deduced as to their likely endotoxic potential, or lack of 
it. But with the knowledge that endotoxic potential can vary in the most fundamental 
way across Gram-negative bacteria, from agonistic to weakly active to inactive to 
antagonistic, it should be incumbent on the cyanobacteria research community to 
cease attributing biological activity and clinical symptoms to cyanobacterial LPS 
without research evidence. Cyanobacteria may not be typical Gram-negative 
organisms because of their unusual cell wall architecture, and cyanobacteria will have 
experienced very different selection pressures to gut-dwelling Gram-negative bacteria, 
which may be reflected in different lipid A structures.  
 
 
 
LPS and infection 
 
Much research into LPS and lipid A has understandably concentrated on the severe, 
life-threatening host responses to circulating LPS that constitute Gram-negative 
septicaemia and septic shock. Many experimental models have utilised either in vitro 
studies of isolated cell lines or animal and human studies where LPS is exposed to the 
circulation by parenteral injection.  
 
The matter of the degree to which cyanobacterial LPS/lipid A can stimulate 
mammalian cytokine networks under experimental conditions, which remains largely 
unanswered, is only one aspect in the understanding of cyanobacterial LPS and the 
gastro-intestinal, respiratory and cutaneous illnesses which have been attributed to 
 17
contact with it. The other side of the story that needs to be considered is the 
mechanism by which cyanobacterial LPS might (and might not) stimulate endotoxic 
responses by the various exposure routes: ingestion, inhalation and contact. The 
following discussion will briefly review the association between acute gastrointestinal 
illness and Gram-negative bacterial LPS. Cutaneous responses to LPS will be briefly 
discussed.  
 
 
Terminology: infection, pathogen 
 
Infectious diseases are characterised by several discrete steps: bacterial adhesion to 
the host, colonisation within or on the host, and evasion of host defences [31, 47 
(p.37)]. The only references in the literature that describe cyanobacteria as invasive, 
infectious organisms were from two authors:  
 
• Rank [104-106] put forward the hypothesis that a chronic, low-virulence 
infestation by cyanobacteria growing heterotrophically may explain the aetiology 
of arteriosclerosis in humans and homeothermic animals. The author bases his 
theory on ecological data, examining the geographical, demographic and 
historical distribution of the disease. Routes of infection are posited to be 
ingestion of unfermented milk, public water supplies drawn from surface waters 
as distinct from groundwater [105, 106], and earth-contaminated food and other 
objects [104]. The author also critiques the three theories of the pathogenesis of 
arteriosclerosis that were current at the time (response-to-injury, lipid hypothesis, 
and monoclonal hypothesis) and suggests laboratory studies to replicate and study 
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the disease. Such studies do not subsequently appear in the literature, and no 
further reference to the cyanobacterial infection hypothesis can be found.  
• Ahluwalia et al [107] and Ahluwalia [108, 109] posited the theory that 
Microcystis aeruginosa is the causative organism of the mostly tropical, water-
exposure-related invasive disease rhinosporidiosis. However, this theory has been 
disputed; convincing and probably conclusive evidence appears to place the 
eukaryotic protist Rhinospiridium seeberi as the causative organism (see Author’s 
reply to Ahluwalia [109]). 
 
Most public health workers would presumably place cyanobacteria-related illnesses in 
the context of environmental exposures, as distinct from familiar diseases due to 
communicable infectious bacteria, which, in many cases feature transmissible 
illnesses, secondary to the original reservoir of infection. Cyanobacteria-related illness 
is viewed as intoxication, rather than infection, usually on the basis of a sudden onset 
of symptoms occurring soon after exposure (i.e. without an incubation period), and 
lack of secondary cases [110]. Giesecke [111 (p.12)] defines infectious disease as “all 
diseases caused by micro-organisms”, with sub-definitions of communicable and 
transmissible disease (communicable disease: capable of being transmitted from an 
infected individual to another person, directly or indirectly; transmissible disease: able 
to be transmitted from one individual to another by ‘unnatural’ routes). Whether 
cyanobacteriologists would embrace that definition of infectious disease is moot, but 
most would agree that cyanobacteria-related diseases are neither communicable nor 
transmissible. Exotoxin-producing cyanobacteria certainly fit the dictionary definition 
of pathogenic (i.e. disease-causing) organisms; the reader’s attention is drawn to the 
distinction between infectious (implying colonisation and evasion of host defences) 
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Gram-negative bacteria and non-infectious cyanobacteria in the following discussions 
on LPS and G-I and dermal illnesses. 
 
 
Mechanisms of vomiting and its relationship to LPS activity 
 
Nausea and vomiting are normal physiological responses to the ingestion of toxic 
substances; they are essential defences because they are the end result of the actions of 
sensorimotor systems that operate to identify and rapidly expel hazardous substances 
from the upper G-I tract [112-114]. The two main sensory systems that direct the 
emetic response are local, associated with the gut mucosa (pre-absorptive response), 
and central, specifically the chemoreceptive trigger zone of the area postrema, located 
in the dorsal surface of the medulla oblongata (post-absorptive response) [115-117]. 
Stimulation of chemoreceptors in the stomach, jejunum and ileum by irritant 
chemicals such as hypertonic saline, copper sulfate or mustard, or by bacterial 
enterotoxins, leads to the activation of vagal sensory afferent nerves to the brain. 
Vagal efferent processing through the enteric nervous system stimulates enteric motor 
neurons to effect emesis [112, 114, 116, 117]. Emetic chemoreceptors are also found 
in the vascular system; activation of these chemoreceptors will also initiate nausea and 
vomiting [112]. Endogenous mediators of emesis such as dopamine, acetylcholine and 
enkephalin are reported [112]. Prostaglandins have well-known emetic actions [118].  
 
Circulating E. coli LPS is a potent emetic stimulant. In a series of experiments using 
piglets, Girod et al [119] showed that parenteral administration of LPS provoked 
vomiting (as well as fever, rigors, purpura, diarrhoea and drowsiness). The authors 
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suggested that LPS stimulates vomiting by means of cytokine-induced prostaglandins 
and other endogenous mediators acting both centrally and on vagal afferents. Other 
animal studies have demonstrated the emetic action of LPS [120].  
 
The area postrema is reported to be the primary sensory area involved in nausea as 
well as vomiting, although nausea is accompanied by autonomic excitation, whereas 
vomiting is a somatic process independent of the autonomic nervous system [115, 
118]. Presumably LPS-stimulated endogenous mediators are associated with 
symptoms of nausea, which is reported in several studies and reviews of intravenous 
exposure to LPS in human volunteers [45, 59, 63, 64].  
 
To investigate vomiting associated with exposure to cyanobacteria, the appropriate 
research efforts should determine whether cyanobacterial LPS is capable of 
stimulating gut chemoreceptors, or if cyanobacterial LPS can gain access to the 
circulation and stimulate nausea and vomiting centrally. Another point of interest 
should be directed towards the cyanobacterial exotoxins, as to their capacity to 
stimulate either gut mucosal chemoreceptors, vascular emetic chemoreceptors, or by 
endogenous mediators. Bacterial exotoxins such as staphylococcal enterotoxins (SEs) 
are known to stimulate emesis via gut chemoreceptors [113, 114, 121]. Worthy of note 
is that experimental induction of LPS-related emesis is achieved by intravenous or 
intraperitoneal routes [119-124], whereas SEs readily elicit vomiting when 
administered intragastrically [121, 125]. Also of interest with respect to 
cyanobacteria-related G-I illness are some similarities of clinical symptoms in the case 
of staphylococcal food poisoning: enteritis due to ingestion of SEs is characterised by 
rapid onset (1-4 hours) of vomiting ± nausea and diarrhoea, abdominal cramping and 
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dizziness [121, 126]. Staphylococcal food poisoning is an intoxication, not an 
infectious process [126]. 
 
 
Diarrhoea and LPS 
 
One inference that can be drawn from the references that posit cyanobacterial LPS as 
the cause of G-I illnesses (see Table 1) is that these symptoms are not necessarily 
related to exposure to any of the known cyanobacterial exotoxins, the assumption 
being that exposure to – and presumably illness caused by – cyanobacterial LPS can 
occur with or without concurrent exposure to exotoxins (i.e. from non-toxic strains or 
species, or non-production of exotoxins at the time of exposure). However, several 
questions need to be answered if LPS is the sole presumptive “G-I-toxin”. A 
hypothesis is needed for the mechanism of cyanobacterial LPS, in the absence of other 
virulence factors, to initiate diarrhoea by the oral exposure route. Another explanation 
for cyanobacterial LPS-related diarrhoea is that the alteration in gut membrane 
permeability may be related to a cytokine cascade generated by circulating 
cyanobacterial LPS, but again, a hypothesis is needed to explain the exposure route 
for the LPS to overcome innate immune intestinal defences in order to gain access to 
the circulation.  
 
Some observations on the behaviour of Gram-negative bacterial LPS in the gut serve 
to cast doubt on the suspicions that cyanobacterial LPS alone is responsible for 
initiating acute gastro-intestinal illness in humans by the oral route: 
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• Commensal gut flora: The human intestinal tract houses an enormous population 
of bacteria, many of which are Gram-negative. The Enterobacteriaceae are found 
in normal faecal flora at some 108-109 per gram [127]. The number of microbes in 
the gut lumen exceeds the number of eukaryotic cells in the human body by an 
order of magnitude [47 (p.16), 128], an observation that may lead some to 
unkindly suggest that the principal reason for human existence is to serve as bags 
for the housing and transport of bacteria. Nanthakumar et al [129] note that 
mature enterocytes are 100 to 1,000 times less sensitive to LPS than neutrophils 
and hepatocytes, which is not surprising since they are exposed to Gram-negative 
bacteria and their endotoxins since birth when the gut is colonised.  
 
• Non-virulent strains: Most Gram-negative organisms are non-pathogenic. 
 Pathogenicity involves a complex interaction between host-related and 
 specific microbial virulence factors - the latter including pili, fimbriae and heat 
 shock proteins [130, 131]. Infectious, i.e. colonising, microbes are the most 
 common cause of diarrhoea worldwide; pathogenic strains commonly cause 
 disease by the action of enterotoxins [132]. That virulence factors other than 
 lipid A structures of LPS are responsible for gastro-intestinal disease is seen in the 
 protective effects of attenuated or mutant Gram-negative bacteria when used as 
 live oral vaccines against pathogenic strains [130, 133-135]. Some E. coli strains 
 are used as probiotics for the treatment of gastrointestinal disease and infection 
 prophylaxis in neonates [136]. 
 
• Anecdotal reports of consumption of non-hazardous cyanobacteria: Heaney 
[38] reports observations of cattle seen drinking from two Irish lakes affected by 
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thick scums of Anabaena flos-aquae and Aphanizomenon flos-aquae without ill 
effect. Author IS can add a similar observation: during recruitment for an 
epidemiology study [137] at Lake Coolmunda in southern Queensland, a frank 
Microcystis aeruginosa bloom was in attendance. A group of six or seven dogs 
were seen playing vigorously in the water, and three dogs were observed drinking 
from it. The owners of the animals were questioned the following day; all denied 
observing any adverse effects. The consumption of Spirulina and other 
cyanobacteria provides further evidence that cyanobacterial LPS cannot all be 
harmful. Cyanobacteria as food, medicine and livestock feed will be discussed 
later in this review.  
 
Oketani et al [138] state that orally administered LPS is not harmful to animals, which 
is in stark contrast to LPS administered parenterally. Evidence for harmful effects of 
orally administered LPS is difficult to gather from the literature because of the 
overwhelming number of publications describing experimental use of LPS as an in 
vitro and in vivo immune stimulant. The authors of this review have been able to find 
two reports of in vivo LPS activity by the oral route: Yang et al [139] showed that oral 
administration of E. coli LPS enhanced the progression of hepatoma in rats treated 
with thioacetamide. Yoshino et al [140], using a mouse model of autoimmune disease, 
demonstrated that orally-dosed LPS exacerbated collagen-induced arthritis. These 
models of liver disease and autoimmunity are not applicable to the concept of acute G-
I symptoms caused by cyanobacterial LPS in presumably healthy people in 
recreational settings and through cyanobacterial contamination of drinking water 
supplies. However, they highlight the importance of gut mucosal immunity. LPS and 
other microbial products are constantly sampled by gut-associated lymphoid tissues, 
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which contain the largest assemblage of immunocompetent cells in the body [128]. 
Translocation of small amounts of LPS from the gut lumen across the epithelium and 
into the portal circulation is an important immune-stimulating process, with Kupffer 
cells in the liver playing an important role in clearance of LPS from the circulation 
[128]. LPS and other bacterial products from the normal gut flora can be a source of 
infection and sepsis when the integrity of the gut mucosa is disrupted. This occurs in a 
variety of disease states, including hypovolaemic shock, burn injury, trauma, acute 
liver failure, pancreatitis, cirrhosis and inflammatory bowel disease [128].  
 
Roth et al [141] suggest that endogenous (i.e. gut-derived) LPS is a potent synergist of 
the toxicity of a range of structurally and functionally unrelated hepatotoxic 
xenobiotic agents. The authors put the proposition that hepatotoxicity associated with 
some chemicals is indirectly caused by primary damage to the intestinal tract, which 
allows increased translocation of bacterial LPS into the portal circulation. The liver is 
then exposed to harmful levels of LPS, and the ensuing liver injury resembles that 
caused by large doses of LPS: changes in sinusoidal and parenchymal cells, neutrophil 
and platelet accumulation in sinusoids, then multifocal hepatocellular degeneration 
and necrosis. Yee et al [142] showed that co-administration of individually non-toxic 
doses of LPS and the alkaloid phytotoxin monocrotaline produced significant liver 
injury, characterised by midzonal and centrilobular apoptotic and necrotic changes, 
coagulation and congestion, and loss of sinusoidal architecture. Ganey & Roth [143] 
propose that the activation and increased expression of various soluble mediators, 
signalling molecules and cellular processes are crucial events in the augmentation of 
xenobiotic toxicity by bacterial LPS, and that the mechanisms of toxicity are complex 
and variable. 
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 Purified microcystins as well as microcystin-producing and cylindrospermopsin-
producing cyanobacteria have been shown in accidental poisonings and through in 
vivo and in vitro experimental work to damage the gastrointestinal tract  [36, 144-
150]. The possibility should be considered that cyanotoxins and LPS (from 
cyanobacteria and/or from gut-dwelling heterotrophic bacteria) may cross a disrupted 
gut mucosal barrier and enhance the pathological effects of cyanobacterial exotoxins.  
   
 
 
LPS and cutaneous reactions 
 
As with LPS and oral exposure, searching bibliographic databases for evidence of 
LPS/endotoxin as the primary cause of acute clinical dermatoses is a difficult task, 
again because of the many citations of in vitro immunology work using LPS to 
investigate various dermal cell processes. As a starting point, dermatology textbooks 
were perused, yet only one of a dozen or so standard texts made any reference to 
either LPS or endotoxin: Rietschel & Fowler [151 (pp.549-50)] describe a single case 
report of a hospital worker who suffered dyshidrosis (a vesicular or vesicopustular 
eruption on the palms of the hands), which was linked to endotoxin in latex gloves. 
Various dermatoses are clearly associated with either superficial or systemic infection 
by many Gram-negative organisms, most notably Pseudomonas aeruginosa [152 
(pp.289-305)]. However, it is unreasonable to compare mechanisms of cutaneous 
disease from colonising Gram-negative bacteria to those due to cyanobacteria solely 
on the basis that both organisms contain LPS.   
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Cyanobacterial LPS 
 
Literature searches using PubMed and Web of Science with the search terms 
(cyanobacteria* OR blue green alga*) AND (LPS OR endotoxin) revealed 17 
publications that describe the extraction ± purification of cyanobacterial LPS. The 
Westphal hot phenol/water method was used in 15 of these studies (described in [153 
(Sections 6.2.1.1 & 6.2.1.1.1)]). Jürgens et al [154] used a sucrose density 
centrifugation and Triton X-100 extraction, and Papageorgiou et al [155] compared 
the phenol/water method with novel extraction methods. Raziuddin et al [156] used 
chloroform and acetic acid extraction to isolate lipid A from their LPS extract. Table 2 
lists the studies in which cyanobacterial LPS were tested for lethality in mice. All 
doses were reported in the original papers in terms of dose per mouse; these doses 
have been converted to mg/kg body weight for comparison purposes in Table 2. An 
assumed weight of 20g was applied to mice for the studies in which the authors did 
not report the weight of their animals.  Note that the study of Scholtissek et al [157] 
used galactosamine-sensitised mice, so their LPS doses are not directly comparable to 
those given in the other studies; a similar situation applies with the study of Katz et al 
[158], where adrenalectomised mice were used. Adrenalectomy sensitises mice by 
three orders of magnitude to the lethal effects of LPS [159, 160]. By way of 
comparison, some examples of reported lethal concentrations of Enterobacteriaceae 
LPS are: 5-20mg/kg [161], 6mg/kg [162] and 24mg/kg [160] (LD50 concentrations in 
various strains of LPS-sensitive mice; assumed weight of mice = 20g) to LD80 
concentrations of 10-23 mg/kg [163]. 
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 In addition to lethality, various other toxicity endpoints were examined in some of the 
studies listed in Table 2 and others. Buttke & Ingram [164], Keleti et al [165] and 
Keleti & Sykora [166] investigated the local Shwartzman reaction, which is a 
dermonecrotic lesion elicited in rabbits by subcutaneous preparative and intravenous 
provocation injections. Positive Shwartzman reactions were generated by Agmenellum 
quadruplicatum LPS, Schizothrix calcicola LPS and Anabaena flos-aquae LPS, but 
not by Oscillatoria tenuis LPS [164-166]. These results should be regarded as 
qualitative, as no reports were made of quantitative measurements of lesions, which 
can be done by various methods [167, 168]. However, the local Shwartzman response 
to A. quadruplicatum LPS led the study authors to describe Agmenellum LPS as “a 
less effective endotoxin than Salmonella LPS” [164]. The Shwartzman reaction to A. 
flos-aquae LPS was reportedly “weakly positive” [166].  Keleti & Sykora [166] also 
used a rabbit isolated ileal loop assay, which did not show any positive findings from 
the three cyanobacterial LPS isolates injected. Weise et al [169] tested A. nidulans 
LPS for pyrogenicity in rabbits, reporting a tenfold lower response than that seen from 
E. coli LPS.  Schmidt et al [170] also tested the LPS from two Synechococcus strains 
for pyrogenicity, with maximum increases in rabbit body temperature of 1.50C after 
injection of up to 1mg/kg. The authors report that these doses are some three orders of 
magnitude higher than those required of Salmonella LPS to achieve the same effect. 
LPS extracted and purified by author IS and also by Papageorgiou et al [155] were 
investigated for their potential to affect thermoregulation in a mouse model. LPS from 
several cyanobacterial isolates induced sickness behaviour and transient hypothermia 
at doses of 70mg/kg i.p.; similar responses in positive control animals were seen after 
i.p. injection of 4mg/kg E. coli LPS. Cyanobacterial LPS doses of  7mg/kg also 
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initiated  transient hypothermia and sickness behaviour, although at markedly lower 
intensity and duration than was seen with E. coli LPS at 4mg/kg [153 (Ch.6)].  
 
Most workers concluded that the cyanobacterial LPS they examined were weakly 
toxic when compared to the activity of positive control heterotrophic bacterial LPS. 
The exception was the work of Best et al [171], who investigated the potential of 
isolated cyanobacterial LPS to reduce the activity of glutathione S-transferases (GSTs) 
in Zebra fish embryos. They reported that cyanobacterial LPS reduced microsomal 
and soluble GSTs in vivo to a greater extent than LPS from E. coli or Salmonella 
typhimurium. The authors suggested that such reduction in GST availability may 
deleteriously affect the ability of organisms to detoxify microcystins, presumably 
through decreased utilisation of glutathione (GSH) for conjugation reactions. This 
would seem to be a reasonable assumption, although other interpretations of this 
finding are possible. While the GSH system is an essential intracellular redox buffer, 
preventing oxidative injury, it is also an important participant in many cellular 
functions, including DNA and protein synthesis, metabolism, cell growth and amino 
acid transport [172, 173]. Many enzymes are GSH-dependent, including glutathione 
transferases [174]. GSH is also an essential component of some immune functions 
such as apoptosis, T-lymphocyte signalling and proliferation, and activation of the 
nuclear transcription factor NFκB [173, 175-181]. It is these immunological functions 
of the GSH system that present as somewhat paradoxical: glutathione depletion has a 
protective effect on various models of apoptotic and necrotic liver injury [178, 182-
184]. Glutathione depletion has also been shown to prevent LPS-induced 
inflammatory lung injury by attenuating neutrophil activation and sequestration [185, 
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186]. Glutathione depletion has been proposed as a novel anti-inflammatory 
pharmacotherapy [183, 187]. Dröge et al wrote in 1994 that:  
 
“It is clear that GSH is one of the limiting factors that determine the 
magnitude of immunological functions in vitro and in vivo…we must be 
prepared to reevaluate one of the central dogmas concerning the role of GSH. 
GSH was viewed mostly as an important anti-oxidant that protects cells 
against oxidative stress” [175]. 
 
So the findings of Best et al [171], where cyanobacterial LPS markedly reduced GSTs 
in fish embryos after 24 hour exposures, may indicate an LPS-antagonist response,  an 
anti-inflammatory response displaying a different time course to that seen with 
heterotrophic bacterial LPS, or a consequence of decreased GSH availability, as 
intracellular GSH efflux increases with the onset of apoptosis [176]. GSTs can be 
inhibited by GSH conjugates, i.e. their reaction products [188], so this possibility may 
also need to be considered. In any event, and insofar as innate immune responses in 
fish embryos can be equated to mammalian cellular activities, these responses are 
likely to be very complex, with numerous endogenous mediators, feedback loops and 
time-dependent variation. As an example, the chemoprotecant oltipraz, which is 
thought to exert anticarcinogenic effects through induction of cytochrome P450 (CYP) 
enzymes, is now known to transiently (within 24 hours) inhibit some important CYPs 
and GSTs in vitro and in vivo. Animals treated for three days showed two-fold-plus 
increases in the same enzymes [189, 190]. We would be interested to see time-course 
studies that replicate the work of Best et al [171], perhaps continued over several 
days.  
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 In addition to the studies cited above, nine reports describe the isolation and 
purification of cyanobacterial LPS for various biomedical, biochemical or structural 
studies, but no toxicological endpoints were investigated [28, 154, 191-197]. The 
topic of cyanobacterial LPS was reviewed by Weckesser et al [27], and Mayer & 
Weckesser [198]. These reviews are especially valuable in that they contrast the work 
done on other photosynthetic prokaryotes, especially the purple non-sulfur bacteria, 
some of which have been shown to have lipid A structures that are LPS antagonists, as 
discussed above. No cyanobacterial lipid A structures have been described to date.  
 
In addition to work done on isolated and purified LPS, some reports discuss the 
activity of cyanobacterial LPS by use of the Limulus amoebocyte (LAL) assay. This is 
a highly sensitive test, though there are trade-offs in terms of specificity, with other 
bacterial products such as peptidoglycan and glucan capable of registering positive 
responses [47 (p.140), 199, 200]. The assay may not always be a reliable predictor of 
cellular and in vivo responses [201]. The study of Rapala et al [202] had some 
significant findings pertaining to the topic of presumed toxicity of cyanobacterial LPS. 
The authors used the LAL assay to test 26 axenic strains from five cyanobacterial 
genera; all responses were at least five orders of magnitude lower than reactions to E. 
coli LPS, and several were below the assay’s detection limits. This suggests that the 
lipid A structures of these LPS have some significant and fundamental structural 
differences to endotoxic lipid A, as the LAL assay does not react to some unusual or 
modified lipid A structures [85].  
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Spirulina platensis: the importance of exposure route 
 
S. platensis has a long history of use as a foodstuff, dietary supplement and livestock 
feed additive, with its probable use dating back to the ninth century in Africa, and the 
14th century in Mexico [203]. Spirulina is classified taxonomically under the genus 
Arthrospira, order Oscillatoriales; A. maxima and A. fusiformis are grown 
commercially in mass culture, but usually designated as “S. platensis” [204]. The use 
of this cyanobacterium was comprehensively reviewed by Ciferri [205], who 
concluded that extensive nutritional and toxicological testing has shown it to be a safe 
and valuable protein source. The use of Spirulina was briefly reviewed along with that 
of other edible microalgae by Kay [41], who cited Ciferri [205] in stating that some 
“negative effects” of Spirulina feeding were seen in multigenerational studies and 
mutagenicity tests. However, this appears to be a misinterpretation on the part of Kay 
[41], as Ciferri [205] described “negative results” from these studies. The original 
publications cited by Ciferri [205] were unobtainable. More recent studies seem to 
support the suggestion that consumption of Spirulina is not harmful, and enhances 
various immune functions [206-210].  
 
A single case report is the exception to the rest of the literature. Iwasa et al [211] 
describe a 52-year-old male taking antihypertensive, hypolipidaemic and 
hypoglycaemic pharmacotherapy who developed abnormal hepatic enzyme levels two 
weeks after taking Spirulina, presumably on a regular basis. Liver function tests 
showed a significant deterioration over the following three weeks, after which he was 
hospitalised. Although a physical examination was unremarkable, a liver biopsy 
revealed some degenerative changes. Serological studies for a range of viruses were 
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negative. His medications and Spirulina were withdrawn, after which his hepatic 
function rapidly returned to normal. Hepatotoxicity in this case was attributed to 
consumption of Spirulina, on the basis of temporal relationships between liver 
function abnormality and recovery with consumption and withdrawal of Spirulina, 
although possible interaction effects with the medications would have been worth 
considering. This may have been the case with simvastatin, the cholesterol-lowering 
agent this individual was taking. Simvastatin causes increased proinflammatory 
cytokine production, and it can potentiate inflammatory responses induced by 
bacterial products [212].  
 
Recent work has demonstrated that A. fusiformis in Kenyan soda lakes is capable of 
producing the cyanobacterial exotoxins microcystin-YR and anatoxin-a [213, 214]. 
The implications of this finding are important because cyanobacterial poisoning is 
implicated in mass mortalities of Lesser Flamingos in the Rift Valley, and A. 
fusiformis is the principal food source for these animals [215, 216]. Common 
toxigenic cyanobacteria such as Anabaena and Microcystis are also found in these 
lakes, and periodically dominate the phytoplankton profile [217], so presumably 
toxin-producing genes are being transferred between these genera in the field.  
 
The long-standing and widespread consumption of Arthrospira spp. illuminates the 
importance of considering the route of exposure in toxicology studies, and the dangers 
in this case of presumptive inference of disease from the findings of parenterally 
administered LPS. Tornabene et al [218] reported a lethal dose of Spirulina platensis 
LPS in the range of 400mg/kg (i.p. mouse), although those findings are not supported 
by the work of Stewart, where Spirulina LPS i.p. injections of 350mg/kg failed to 
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induce either thermoregulatory change or sickness behaviour signs [153 (Sections 
6.4.2.4 & 6.4.2.6)]. However, Falconer [219] reported that cell lysates of Spirulina 
were highly toxic to mice when administered by intraperitoneal injection.  
 
Other cyanobacteria are consumed as foods, medicines and dietary supplements. 
Wild-harvested Aphanizomenon flos-aquae was over a decade ago reportedly 
“consumed by thousands of people without incident” [41], although the lake that 
produces the commercially available product (Lake Klamath, Oregon) is sometimes 
subject to contaminating growth of Microcystis spp., and some A. flos-aquae end-
product batches contaminated with microcystins have since been found [220-222]. A 
Canadian survey analysed for microcystins in cyanobacterial products 
(Aphanizomenon, Spirulina and unidentified cyanobacteria) but did not present the 
results according to the component genera, so it is not clear whether Spirulina 
products (presumably originating from commercial mass cultures) contained 
microcystins [223].  Nostoc commune, a terrestrial species, has a long history of use in 
China and Scandinavia as food and medicine [224]. The widespread use of these 
products serves as a reminder that some cyanobacteria, and therefore their LPS, are 
not harmful by the oral route.  
 
 
LPS by inhalation 
 
In our opinion, the sole natural exposure route that might explain aquatic 
cyanobacterial LPS-related illness is via inhalation of aerosolised cells or fragments. 
Extrapolating from the understanding of Gram-negative bacterial LPS on the 
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respiratory system (as have most if not all of the authors cited in Table 1 for the 
presumed involvement of cyanobacterial LPS on various disease states), there is a 
significant and increasing body of literature on the association between endotoxin and 
pulmonary disease, including asthma, chronic obstructive airway disease and 
emphysema. Intact bacteria and cell wall fragments are readily aerosolised; 
bioaerosols of Gram-negative bacteria are widespread contaminants of soils, water 
and living organisms [225, 226]. Exposure to airborne endotoxin has been associated 
with a range of occupational respiratory diseases, in industries where high 
concentrations of organic dusts are liberated, e.g. various agricultural settings, cotton 
milling, brewing, waste processing [225, 227]. Endotoxin is also found in high 
concentrations in air pollution and household dust [228]. Endotoxin in some aquatic 
environments can be aerosolised to disease-related concentrations: Rose et al [229] 
investigated outbreaks of granulomatous pneumonitis affecting lifeguards at an indoor 
swimming pool, with some affected chronically. Gram-negative bacteria, principally 
Pseudomonas spp, colonised water spray systems in the facility, and increased 
endotoxin in bio-aerosols was linked to the illnesses.  
 
Michel [227] reviewed experimental inhalation studies of LPS: 4-12 hour periods of 
dyspnoea, chest tightness, myalgia, shivering, fatigue and malaise with or without 
fever were reported in a minority of normal subjects. Impaired pulmonary function in 
the form of bronchoconstriction, changes in non-specific bronchial 
hyperresponsiveness and reduced alveolar-capillary diffusion were demonstrated. 
Asthmatic subjects responded with significant bronchoconstriction lasting five or 
more hours at doses of 20 µg, whereas normal subjects required doses of 80 µg or 
more to produce moderate bronchoconstriction [227]. Of interest is the observation 
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that LPS-induced lung changes are associated with neutrophil activation, whereas 
purified allergen extracts induce bronchial eosinophilia in asthmatic subjects [227, 
230]. Normal subjects exhibit a broad range of responses to inhaled LPS: 9% of 
subjects developed airway obstruction after low-dose inhalation, and 15% showed a 
negligible airway response to high doses of LPS [228, 231]. Polymorphisms in genes 
coding for Toll-like receptors, especially Toll-like receptor-4, appear to be important 
determinants of variability in human responses to inhaled endotoxins. Arbour et al 
[232] showed that a TLR4 sequence mutation is associated with an endotoxin 
hyporesponsive phenotype in humans.  
 
 Schwartz [228] describes asthma as a complex, heterogeneous disease with multiple 
clinical sub-types, polygenic inheritance and is influenced by many different 
environmental exposures. Endotoxin is one such exposure, which causes a 
biologically unique form of asthma [228]. However, exposure to endotoxin early in 
life may confer beneficial effects: growing up on a farm and exposure to livestock is 
reportedly associated with a significant reduction in atopy, and there is an inverse 
correlation between house-dust endotoxin concentration and allergen sensitisation 
[233-235]. This so-called “hygiene hypothesis” for allergic diseases describes the 
concept that allergy results from an imbalance in the T-helper cell (Th) subset. 
According to this theory, exposure to bacterial and viral pathogens in the prenatal and 
early childhood periods prevents the induction of allergen-associated Th2 cells by 
establishing a Th1-biased immunity [233, 236]. However, the hygiene hypothesis is 
complex and controversial, with contradictory observations and refinements to the 
theory appearing in the literature. Interested readers are directed to some recent 
reviews and updates: [236-239] 
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 LPS and allergens initiate inflammatory processes in the airways through different 
pathways and cytokine cascades: LPS is recognised by innate immune cells, 
principally alveolar macrophages, which generate pro-inflammatory cytokines such as 
IL-1, TNF-α and IL-8; the latter cytokine recruits and activates neutrophils. LPS also 
generates IL-12, which inhibits IgE responses. Allergens generate IL-4, IL-13 and IL-
5, the latter cytokine being an activator of eosinophils [236].  
 
In the context of environmental exposures, endotoxins and allergens often occur 
together; synergistic effects are important considerations in that airway responses to 
combinations of LPS and allergen are reportedly greater than to either substance alone 
in atopic asthmatics [236, 240]. 
 
The impact of cyanobacteria on respiratory symptoms in atopic individuals is worthy 
of investigation, and may involve protein allergens and cyanobacterial endotoxin from 
both toxic and non-toxic blooms. However, the relative burden of cyanobacterial 
endotoxin to respiratory morbidity will depend on the capacity of the LPS of any 
given cyanobacterial species to act as an LPS agonist, or as an LPS antagonist, or be 
biologically inactive; such properties are as yet largely undetermined.  
 
An equally important research effort should be directed towards the capacity of 
inhaled cyanobacterial exotoxins to generate immunologically non-specific responses 
(i.e. in unsensitised individuals) in the bronchial tree. Microcystin-LR appears to be 
able to efficiently gain access to the circulation by both intranasal and intratracheal 
routes [241-243], but Gram-negative bacterial endotoxin delivered by inhalation does 
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not cross into the pulmonary vasculature to enter the circulation, and at least one 
endotoxin-stimulated cytokine – TNF-α – is compartmentalised in the airways [236, 
244, 245]. What is open to question is whether the serious cases of pneumonia 
reported after recreational exposure to cyanobacteria (see Stewart et al [246]) may be 
explained by the induction of an inflammatory response by inhaled cyanobacterial 
exotoxin, progressing to recruitment and activation of neutrophils and which is 
confined to the pulmonary alveolar compartment. The possibility is also open as to 
whether less dramatic reports of respiratory illness may also be explained by a similar, 
albeit self-limiting process, in healthy, non-atopic individuals. Of course, this 
speculation does not exclude the likelihood of different, overlapping mechanisms of 
disease that may explain these phenomena – protein allergens in some cyanobacteria 
may provoke symptoms in atopic individuals, such symptoms possibly being 
exacerbated by the presence of cyanobacterial and/or epiphytic bacterial endotoxins.  
 
Cyanobacterial exotoxins may have the capacity to generate respiratory illness in non-
atopic individuals, with endotoxins from cyanobacteria or commensal organisms 
possibly augmenting the symptoms. The potential for cyanobacterial and/or 
contaminant endotoxin alone to produce symptoms by inhalation exposure remains 
open, given the observation that LPS can produce measurable airway function changes 
in animal models and in some healthy individuals [231, 247-249].  Yet it remains 
unclear whether such experimentally-induced changes in the airway function of 
healthy volunteers correlate with symptoms of respiratory dysfunction.  
 
 
Concluding remarks 
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 Lipid A, the endotoxic moiety of LPS, was in previous decades thought to remain 
constant across different Gram-negative bacteria [97]. This is now understood to be 
incorrect; many non-enteric bacteria are seen to vary in their lipid A structures. 
Because the biological activity of lipid A is determined by its structure, the toxic 
potential of non-enteric bacteria can vary. Gram-negative organisms occupying 
different ecological niches will not have the same requirements for growth, and their 
outer membranes can be expected to vary in order to meet different environmental 
conditions [31]. Endotoxic potential cannot be assumed to be lacking in the LPS of 
non-enteric bacteria, however, as seen in the high LPS agonist activity of lipid A from 
the non-pathogenic purple non-sulfur bacterium Rubrivivax gelatinosus, as discussed 
above. A similar example is given by another group of non-pathogenic bacteria, 
Rhizobium spp, the LPS from some of which are comparable to that of enterobacterial 
LPS in lethal toxicity and cytokine-inducing activity [250, 251]. Determining the lipid 
A structures of various nuisance cyanobacteria would be an interesting exercise in 
itself, but regardless of the findings, proponents of the “cyanobacterial LPS is toxic” 
cause need to define plausible exposure routes to allow LPS to signal host receptors 
and initiate a pathogenic cytokine cascade.  
 
From the discussion in this review, the authors will put the hypothesis that oral 
consumption of non-toxic cyanobacteria, i.e. absolutely or essentially free of any of 
the known cyanobacterial exotoxins, will not result in either vomiting or diarrhoea. 
This hypothesis would be falsified by experiments that show isolated cyanobacterial 
LPS or non-toxic crude extracts can cause gastrointestinal signs and/or pathology in a 
suitable model. The impression of these authors is that reports of G-I symptoms in 
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humans exposed to cyanobacterial products are indications of innate defences being 
signalled by exotoxins that have breached the intestinal barrier. Once this occurs, and 
gut permeability is sufficiently disrupted, LPS may well synergise the pathology of 
cyanotoxins, especially the hepatotoxins. From what little is known to date about the 
toxic potential of cyanobacterial LPS, i.e. that they are weakly toxic compared to 
those of the Enterobacteriaceae, gut-derived LPS would seem to be the more likely 
candidate for augmenting the pathology of cyanotoxins.  
 
In vivo studies of oral exposure to cyanotoxins would be well served by use of a 
vomiting-capable model, i.e. non-rodent experiments. 
 
There does not appear to be good evidence that cyanobacterial LPS are likely to 
initiate cutaneous reactions in healthy people exposed in recreational or occupational 
settings. Cutaneous reactions to cyanobacteria are discussed in detail elsewhere [252-
254].  
 
Exposure to bio-aerosols containing cyanobacterial endotoxins may be worthy of 
investigation, but we are not convinced that cyanobacteria-related acute respiratory 
illness in non-atopic, non-allergic individuals is not equally or more likely to be 
explained by inhalation of cyanobacterial exotoxins. If some of the exotoxins turn out 
to possess ligands that signal innate immune responses (discussed further in [153 
(Ch.7)]), then the large pool of resident alveolar macrophages would be prime 
candidates for involvement in respiratory defences. The outbreaks of bath-water fever 
in Scandinavia and Africa (see accompanying review by Stewart et al [246]) were, in 
our opinion, suspicious of involvement by cyanobacterial exotoxin breakthrough into 
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reticulated supplies. Similar outbreaks in future should be vigorously investigated for 
cyanotoxins if there is a suggestion of significant cyanobacterial contamination of 
source water.  
 
In conclusion, LPS of the Enterobacteriaceae are potent immunomodulatory and 
immunotoxic bacterial products that stimulate a wide variety of responses in 
mammals, not least of these being a desire to wax lyrical on the topic. Thus: 
 
 “Endotoxins possess an intrinsic fascination that is nothing less than 
 fabulous. They seem to have been endowed by Nature with virtues and 
 vices in the exact and glamorous proportions needed to render them 
 irresistible to any investigator who comes to know them” [255].  
   
And: 
 
 “The dual role of LPS as effector and target makes it a fascinating  molecule 
 which…still hides many miracles. It intrigues at the same time clinical, 
 biological, chemical, and biophysical researchers…” [80]. 
 
Facetiousness aside, these workers are pointing out that there is much to learn about 
the LPS of the most widely studied Gram-negative bacteria, these being the 
Enterobacteriaceae. The understanding of cyanobacterial LPS is utterly miniscule by 
comparison, and we urge caution before continuing to attribute such a disparate range 
of symptoms in humans to contact with these materials without any substantial 
research evidence. Weckesser, Drews and Mayer wrote in 1979 that: 
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  “…the picture obtained with the Enterobacteriaceae cannot be assigned to 
 other Gram-negative bacteria without detailed investigations. Considering the 
 broad spectrum in morphological and physiological diversity of the many 
 taxonomic groups of both photosynthetic bacteria and cyanobacteria, there is 
 a wide open field for studies on the composition of their cell wall.” [27]. 
 
Ressom et al [256 (p.33)] stated that: 
 
 “Given the enormous heterogeneity in LPS from Gram-negative bacteria there 
 is every reason to suspect that the same will apply to cyanobacterial LPS and, 
 due to their taxonomic distance apart, cyanobacterial LPS are likely to be 
 different from those found in Gram-negative bacteria.” 
 
We agree with these statements. 
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FIGURE 1. Schematic of the basic LPS structure. The O-specific polysaccharide is the unit 
that is most exposed to the external environment and so manifests the greatest structural 
diversity; lipid A is the most conserved structure. 
 
 
 
 
 
 62
 63
O
O
O
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 2. Primary lipid A structures: E. coli has a bis-phosphorylated diglucosamine 
backbone with six amide and ester linked fatty acyl chains. The non-endotoxic (and LPS-
antagonist) R. sphaeroides lipid A has an identical disaccharide backbone but has five acyl 
residues, shorter ester-linked primary acyl chains and an unsaturated acyl group. B. fragilis, 
which expresses low endotoxic potential, has a mono-phosphorylated backbone and five acyl 
chains with longer chain lengths than those seen in E. coli. Lipid A from Chromobacterium 
violaceum, like R. sphaeroides, is an LPS antagonist. 
Figures adapted from: Weintraub et al (1989); Rietschel et al (1992) and Takayama & 
Qureshi (1992). 
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     Table 1. Signs and symptoms attributed to cyanobacterial lipopolysaccharides 
GASTRO-
INTESTINAL DERMAL EYE ALLERGIC RESPIRATORY HAYFEVER HEADACHE DIZZINESS CRAMPS 
BLISTERING 
OF MUCOUS 
MEMBRANES 
FEVER REFERENCES 
3           [165, 166, 257-264]  
3 3          [23, 265 (p.16), 266-269] 
3 3 3 3        [6, 12, 270 (p.15), 271, 272] 
 3          [20, 273, 274]  
 3  3        [252] 
   
3 
“allergic and 
toxic responses” 
       [11, 275] 
3 3  
3 
“respiratory 
allergy”  
       [57, 256 (p.33)] 
3 3 3         [26, 276] 
3 3     3 3    [17] 
3      3 3 3   [277] 
 
3 
“cytotoxic” skin 
irritation 
         [278] 
3 3 3   3    3  [19] 
          3 [15, 21, 279] 
3   3       3 [202] 
    3   3   3 [280] 
3 3 3 3 3  3   [281]  3 
 
 
 
 Table 2. Cyanobacterial lipopolysaccharides and lethality 
 CYANOBACTERIUM LETHALITY REFERENCE 
Anacystis nidulans      
non-toxic at 10mg/kg** [169]  
 
A. nidulans KM 
 
2.5mg/kg† (= approx. 800-fold greater 
than Salmonella minnesota LPS) 
 
[158] 
Phormidium spp. (x3) all non-toxic at mean dose of 
333mg/kg 
[282] 
 
 
Schizothrix calcicola non-toxic at 200mg/kg 
   
[165]  
Anabaena flos-aquae UTEX 1444 
Anabaena cylindrica UTEX 1611 
Oscillatoria brevis 
  
non-toxic at 250mg/kg  LD50 130mg/kg   
LD50 190mg/kg    
 
 
[166] 
 
  
Microcystis aeruginosa 006 
 lipid A 
M. aeruginosa NRC-1 
                lipid A 
LD50 approx 45mg/kg** 
LD50 60mg/kg** 
LD50 40mg/kg** 
LD50 approx 45mg/kg** 
[156] 
Spirulina platensis Lb 1475/4a  
    
LD100 425mg/kg** [218] 
  
Microcystis sp. PCC 7806 
 
1 of 3 mice* died at 50μg/kg** [157] 
M. aeruginosa (bloom sample) 
 
no deaths at 70mg/kg (n=5) 
 Cylindrospermopsis raciborskii AWT 205 no deaths at 70mg/kg (n=5) 
[153] 
*galactosamine-sensitised (=TNF-α hypersensitised) 
† adrenalectomised mice 
** assumed weight of mice: 20g 
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